Default company panoramic image


EpiBone's revolutionary, proprietary technology engineers stem cells into anatomically precise, patient-specific bone tissue replacements

  • Stage Product In Development
  • Industry Biotechnology
  • Location New York City, NY, USA
  • Currency USD
  • Founded July 2013
  • Employees 8
  • Website

Company Summary

EpiBone is a revolutionary company that will allow the 2M+ worldwide patients undergoing bone-related surgeries each year to “grow their own bone”. Our pioneering technology utilizes scans of patients' bone defects and their own stem cells to engineer personalized bone grafts. We offer surgeons simplified procedures and patients improved bone formation/regeneration, and shorter recovery times, without the complications of synthetic implants.


  • Default avatar
    Nina Tandon, PhD, MBA
    CEO, co-founder

    Nina Tandon, PhD, MBA is a TED Senior Fellow, MIT and McKinsey alum, researcher at Columbia University’s Lab for Stem Cells and Tissue Engineering, and adjunct professor of Electrical Engineering at Cooper Union.

    She has over 8 years Bioreactor design experience, co-authored 14 journal articles (cited >300 times, H=9), 6 book chapters and 3 patents.

    Fast Company Magazine named her one of their top 100 most creative people in business, 2012

  • Default avatar
    Gordana Vunjak-Novakovic, PhD
    Scientific Advisor

    Gordana Vunjak-Novakovic is a pioneer in the field of Tissue Engineering, and directs Columbia University's Lab for Stem Cells and Tissue Engineering, which developed EpiBone's core technology. She also co-directs NIH's Tissue Engineering Center and Craniofacial Regeneration Center.

    She is well published, and has over 60 licensed, issued or pending patents. In 2008, she was inducted into the Women in Technology International Hall of Fame.

  • Default avatar
    Sidney Eisig, MD, DDS
    Clinical Advisor and Chief Surgeon

    Sidney Eisig is Professor and Director of Oral and Maxillofacial Surgery at Columbia University. He has overseen and/or performed all large-animal preclinical implantations to-date.

  • Default avatar
    Sarindr Bhumiratana
    CSO and co-founder

    Sarindr Bhumiratana is a post-doctoral researcher in the Lab for Stem Cells and Tissue Engineering at Columbia University, where he also completed his PhD. His research focus is controlling tissue matrix assembly of human stem cells toward engineering native-like bone, cartilage, and osteochondral grafts through the use of advanced biomaterials and bioreactor systems. He has co-authored 15 journal articles, 3 book chapters, and 1 patent.

  • Default avatar
    Jon Bernhard, MS

    Jonathan Bernhard, MS, is a current doctoral candidate and NSF and Presidential Fellow in Columbia University’s Lab for Stem Cells and Tissue Engineering. His research focus is endochondral bone formation and the creation of native-like engineered grafts for oseochondral repair. He has extensive experience in biomaterial design and synthesis, stem cell engineering, and bioreactor design and fabrication.

  • Default avatar
    Elisa Cimetta, PhD

    Elisa Cimetta is a New York Stem Cell Foundation Druckenmiller Fellow and Associate Research Scientist at the Lab for Stem Cells and Tissue Engineering, Columbia University. She completed her PhD in Padua Italy, and the Columbia University Postbaccalaureate Business Program. Her research focus is microscale bioreactors, has received multiple honors and fellowships, co-authored 16 journal articles (cited >100 times, H=7), and 3 book chapters.


  • Default avatar
    David Haber, Lowenstein Sandler LLP
    Default avatar
    Tom Pistone, Jameson & Company

Previous Investors

  • Default avatar
    NYC Department of Economic Development ($250k Bioaccelerate Grant, 2011)